Authors:
Gasparini, R
Pozzi, T
Montomoli, E
Fragapane, E
Senatore, F
Minutello, M
Podda, A
Citation: R. Gasparini et al., Increased immunogenicity of the MF59-adjuvanted influenza vaccine comparedto a conventional subunit vaccine in elderly subjects, EUR J EPID, 17(2), 2001, pp. 135-140
Citation: A. Podda, The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine, VACCINE, 19(17-19), 2001, pp. 2673-2680
Authors:
Nicholson, KG
Colegate, AE
Podda, A
Stephenson, I
Wood, J
Ypma, E
Zambon, MC
Citation: Kg. Nicholson et al., Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza, LANCET, 357(9272), 2001, pp. 1937-1943
Authors:
Minutello, M
Zotti, C
Orecchia, S
Di Martino, E
Bastianoni, I
Ypma, E
Moiraghi, AR
Podda, A
Citation: M. Minutello et al., Dose range evaluation of a new inactivated hepatitis A vaccine administered as a single dose followed by a booster, VACCINE, 19(1), 2000, pp. 10-15
Authors:
Chiarle, R
Podda, A
Prolla, G
Podack, ER
Thorbecke, GJ
Inghirami, G
Citation: R. Chiarle et al., CD30 overexpression enhances negative selection in the thymus and mediatesprogrammed cell death via a Bcl-2-sensitive pathway, J IMMUNOL, 163(1), 1999, pp. 194-205
Authors:
Mercuro, G
Pitzalis, L
Podda, A
Zoncu, S
Pilia, I
Melis, GB
Cherchi, A
Citation: G. Mercuro et al., Effects of acute administration of natural progesterone on peripheral vascular responsiveness in healthy postmenopausal women, AM J CARD, 84(2), 1999, pp. 214-218